Ponesimod
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate-to-severe Chronic Plaque Psoriasis
Conditions
Moderate-to-severe Chronic Plaque Psoriasis
Trial Timeline
Jan 1, 2026 → Dec 1, 2028
NCT ID
NCT07362017About Ponesimod
Ponesimod is a phase 3 stage product being developed by Vanda Pharmaceuticals for Moderate-to-severe Chronic Plaque Psoriasis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07362017. Target conditions include Moderate-to-severe Chronic Plaque Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07362017 | Phase 3 | Recruiting |
Competing Products
13 competing products in Moderate-to-severe Chronic Plaque Psoriasis